- Ovarian cancer is a leading cause of death, causes more death than any other female reproductive system cancer
- POAI’s Helomics dedicated to improving clinical decision making for ovarian cancer patients
- Helomics has pioneered testing of drugs on patients’ own tumors to help oncologists individualize treatment options
According to the American Cancer Society, an estimated 21,750 women received a new diagnosis of ovarian cancer this year, and almost 14,000 women will die from the disease (https://ibn.fm/4yfJn). Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women; ovarian cancer causes more deaths than any other cancer of the female reproductive system. These are the numbers that Predictive Oncology (NASDAQ: POAI) is working to change.
For more than a year, Helomics, a wholly owned subsidiary of POAI, has been working with the University of Pittsburgh School of Medicine (“UPMC”) to study the use of artificial intelligence (“AI”) to improve clinical decision making for…
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.